Kavit Handa
The deal gives the Dubai-headquartered investment group full ownership of BB Hamodialyse, which has over 75% of the dialysis market in Moldova and is known for its clinical efficiency and cost-effective treatments. Handa plans to use Moldova as a regional center for training and innovation, exporting its proven dialysis model to underserved markets in Africa and the Middle East.
“Dialysis is necessary to sustain life, but it is expensive,” Handa said. – Moldova has established one of the most efficient dialysis systems in Europe. Using this experience, we can make quality treatment available in regions where access is limited.”
The strategy is in line with Africa Capital’s broader goal of combining commercial growth with social impact. Handa describes the approach as “investing in social impact in the most practical manifestation possible.” The company intends to expand the model to a $100 million business within five years, with a focus on replication, local training and operational efficiency.
For the UAE and GCC countries, where the incidence of diabetes-related kidney disease is rising sharply, this has direct implications. The International Diabetes Federation estimates that more than 73 million adults in the Middle East have diabetes, and the prevalence in the UAE is 16.4%, one of the highest in the world. By combining Moldova’s clinical expertise with Dubai’s healthcare ecosystem, Africa Capital intends to strengthen regional dialysis capabilities and enhance human resource development.
These investments are also in line with Dubai’s ambitions to become a global center for medical innovation, which is in line with the UAE’s National Health Innovation Strategy. They coincide with the growth in economic ties between the UAE and Moldova following the 2025 Visa Waiver Agreement and a more than 20-fold increase in bilateral trade following Expo 2020 in Dubai.
